Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERTHENA-Breast04: Patritumab Deruxtecan vs TPC in HR+/HER2- Breast Cancer
NCT07060807Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2025
- Primary completion
- Jul 2033
- Modality
- Monoclonal Antibodies
- Countries
- 26
01
Overview
Phase 3, randomised, open-label trial of patritumab deruxtecan in breast cancer (2 arms), sponsored by Merck & Co. Primary endpoints: Progression Free Survival at 45 months and Overall Survival at 85 months. Started Jul 2025; status: recruiting.
02
Drugs
patritumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07060807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07060807.